The company maintains a vulnerable capital structure characterized by a persistent negative equity position of $282.3 million and a substantial $1.5 billion total debt burden as of 2026Q1.
| Total Current Assets | 455.98M | 574.01M | 455.02M | 194.84M | 230.74M | 119.82M | 86.16M |
| Cash & Short-Term Investments | 63.83M | 172.36M | 51.43M | 11.16M | 66.43M | 17.56M | 31.69M |
| Cash Only | 63.83M | 172.36M | 51.43M | 11.16M | 66.43M | 17.56M | 31.69M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 106.87M | 153.79M | 251.72M | 87.22M | 71.39M | 53.88M | 33.12M |
| Days Sales Outstanding | 78.03 | 95.74 | 187.63 | 348.17 | 313.82 | 534.83 | 181.45 |
| Inventory | 228.02M | 220.05M | 127.89M | 74.43M | 71.47M | 39.06M | 9.65M |
| Days Inventory Outstanding | 342.42 | 340.98 | 251.9 | 168.9 | 407 | - | - |
| Other Current Assets | 26.18M | 0 | 0 | 0 | 851K | 0 | 5.79M |
| Total Non-Current Assets | 965.19M | 913.08M | 766.38M | 755.25M | 597.71M | 478.16M | 388.26M |
| Property, Plant & Equipment | 495.23M | 356.4M | 409.74M | 356.58M | 268.1M | 205.33M | 176.97M |
| Fixed Asset Turnover | 1.25x | 1.65x | 1.20x | 0.26x | 0.31x | 0.18x | 0.38x |
| Goodwill | 12.51M | 12.84M | 11.33M | 12.06M | 11.64M | 12.37M | 13.43M |
| Intangible Assets | 119.59M | 81.83M | 20.62M | 19.08M | 25.65M | 21.51M | 6.33M |
| Long-Term Investments | 166.5M | 122.93M | 22.71M | 18.49M | 48.57M | 55.31M | 56.68M |
| Other Non-Current Assets | 14.96M | 146.87M | 3.62M | 39.23M | 34.25M | 13.23M | 134.85M |
| Total Assets | 1.42B | 1.49B | 1.22B | 950.09M | 828.44M | 597.98M | 474.42M |
| Asset Turnover | 0.39x | 0.39x | 0.40x | 0.10x | 0.10x | 0.06x | 0.14x |
| Asset Growth % | 80.5% | 21.75% | 28.56% | 14.68% | 38.54% | 26.04% | - |
| Total Current Liabilities | 259.78M | 304.08M | 193.4M | 260.95M | 167.29M | 111.84M | 50.98M |
| Accounts Payable | 97.86M | 126.12M | 67.13M | 80.56M | 49.19M | 28.59M | 11.96M |
| Days Payables Outstanding | 168.78 | 195.43 | 132.22 | 182.81 | 280.11 | - | - |
| Short-Term Debt | 42.51M | 36.92M | 32.7M | 38.02M | 19.92M | 2.77M | 2.5M |
| Deferred Revenue (Current) | 150.17M | 30.36M | 15.98M | 59.18M | 36.91M | 29.69M | 0 |
| Other Current Liabilities | 12.05M | 13.7M | 6.63M | 34.5M | 17.46M | 5.26M | 14.63M |
| Current Ratio | 1.76x | 1.89x | 2.35x | 0.75x | 1.38x | 1.07x | 1.69x |
| Quick Ratio | 0.88x | 1.16x | 1.69x | 0.46x | 0.95x | 0.72x | 1.50x |
| Cash Conversion Cycle | 251.66 | 241.28 | 307.31 | 334.26 | 440.71 | - | - |
| Total Non-Current Liabilities | 1.44B | 1.47B | 1.44B | 1.62B | 1.23B | 621.75M | 1.29B |
| Long-Term Debt | 1.27B | 1.26B | 1.04B | 922.13M | 744.65M | 398.14M | 565.4M |
| Capital Lease Obligations | 553.3M | 138M | 112.14M | 105.63M | 35.37M | 114.84M | 103.47M |
| Deferred Tax Liabilities | 24.59M | 7.87M | 1.81M | 53K | 309K | 150K | 0 |
| Other Non-Current Liabilities | 21.76M | 53.99M | 210.22M | 520.55M | 388.22M | 63.77M | 621.82M |
| Total Liabilities | 1.7B | 1.77B | 1.63B | 1.88B | 1.39B | 733.59M | 1.34B |
| Total Debt | 1.46B | 1.45B | 1.19B | 1.08B | 805.1M | 523.05M | 676.85M |
| Net Debt | 1.39B | 1.28B | 1.14B | 1.06B | 738.67M | 505.5M | 645.16M |
| Debt / Equity | -5.16x | - | - | - | - | - | - |
| Debt / EBITDA | 13.35x | 12.49x | 11.79x | - | - | - | - |
| Net Debt / EBITDA | 12.77x | 11.00x | 11.28x | - | - | - | - |
| Interest Coverage | 0.13x | 1.91x | -0.40x | -3.84x | -5.03x | -0.32x | -1.99x |
| Total Equity | -282.31M | -284.49M | -412.77M | -932.49M | -564.42M | -135.61M | -867.24M |
| Equity Growth % | 157.65% | 31.08% | 55.73% | -65.21% | -316.2% | 84.36% | - |
| Book Value per Share | -0.85 | -1.02 | -1.54 | -4.10 | -2.85 | -4.34 | -27.75 |
| Total Shareholders' Equity | -282.31M | -284.49M | -412.77M | -932.49M | -564.42M | -135.61M | -867.24M |
| Common Stock | 2.93M | 2.93M | 2.83M | 2.28M | 2.13M | 135K | 73K |
| Retained Earnings | -2.41B | -2.41B | -2.44B | -2.21B | -1.65B | -1.14B | -1.04B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 16.6M | 16.68M | 15.05M | 41.38M | 29.14M | 4.67M | 4.97M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Persistent negative equity position
As reported in financial statements, Alvotech's balance sheet trajectory remains characterized by a persistent negative equity position, which deepened to negative $282.3 million in 2026Q1, reflecting the ongoing challenge of financing a capital-intensive biosimilar pipeline through debt rather than retained earnings or equity issuance.
The consistent negative equity suggests that the company's historical losses have eroded its capital base, leaving the balance sheet highly sensitive to further operational setbacks. Investors should monitor whether the company can transition toward positive retained earnings as its commercial portfolio matures, or if the current trajectory necessitates further dilutive financing.
Based on Alvotech's reported figures, total debt has remained elevated at $1.5 billion as of 2026Q1, indicating that the company relies heavily on external leverage to fund its specialized manufacturing infrastructure and R&D activities, which significantly limits its financial flexibility in a volatile interest rate environment.
The reliance on debt to support operations suggests that the company's capital structure is currently optimized for growth at the expense of solvency risk. This leverage profile warrants close investigation, as the interest burden may continue to pressure cash flows and hinder the company's ability to reinvest in its pipeline.
According to recent SEC filings, Alvotech's cash position has fluctuated significantly, dropping to $63.8 million in 2026Q1 from $172.4 million in 2025Q4, which highlights the company's vulnerability to timing mismatches between milestone-driven cash inflows and the ongoing, high-burn requirements of its biologics manufacturing operations.
The erratic nature of the current ratio, which has swung from 0.24 to 2.69 over the last ten quarters, suggests that liquidity management is heavily dependent on the timing of partnership payments. This volatility implies that the company may face periodic liquidity crunches if commercial milestones are delayed or if product uptake fails to meet expectations.
As indicated by the provided data, net PPE has grown to $495.2 million by 2026Q1, reflecting the company's strategic commitment to maintaining a purpose-built, vertically integrated manufacturing facility in Iceland to support its biosimilar production requirements and maintain a competitive cost-of-goods-sold profile.
The concentration of assets in specialized manufacturing equipment suggests an asset-heavy business model that requires high capacity utilization to achieve profitability. Investors should consider whether this infrastructure investment will yield the expected margin expansion or if it will remain a drag on returns due to high fixed-cost overhead.
Based on the company's reported figures, deferred revenue stood at $22.7 million in 2026Q1, representing a decline from previous periods and suggesting that the pipeline of pre-paid milestone payments is being recognized as revenue, which may impact the predictability of future top-line growth.
The downward trend in deferred revenue may indicate that the company is exhausting its existing backlog of milestone-related obligations. This shift warrants further investigation into whether the company can successfully replace these one-time payments with consistent, recurring product sales to sustain its long-term revenue trajectory.
Quick answers to the most common questions about buying ALVO stock.
As of 2025, Alvotech (ALVO) had total assets of $1.49B including $574.0M in current assets.
Alvotech (ALVO) carries total debt of $1.45B, offset by $172.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Alvotech (ALVO) has total shareholders' equity (book value) of $-284.5M ($-1.02 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Alvotech (ALVO) reported a current ratio of 1.89x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.